购物车
- 全部删除
- 您的购物车当前为空
Anatabine dicitrate is a tobacco alkaloid that can cross the blood-brain barrier. It is a potent α4β2 nAChR agonist and inhibits NF-κB activation lower amyloid-β (Aβ) production by preventing the β-cleavage of the amyloid precursor protein.
Anatabine dicitrate is a tobacco alkaloid that can cross the blood-brain barrier. It is a potent α4β2 nAChR agonist and inhibits NF-κB activation lower amyloid-β (Aβ) production by preventing the β-cleavage of the amyloid precursor protein.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | ¥ 1,990 | 期货 | |
10 mg | ¥ 2,910 | 期货 | |
50 mg | ¥ 5,410 | 期货 | |
100 mg | ¥ 8,740 | 期货 | |
200 mg | 询价 | 期货 | |
500 mg | 询价 | 期货 | |
1 mL x 10 mM (in DMSO) | ¥ 2,480 | 期货 |
产品描述 | Anatabine dicitrate is a tobacco alkaloid that can cross the blood-brain barrier. It is a potent α4β2 nAChR agonist and inhibits NF-κB activation lower amyloid-β (Aβ) production by preventing the β-cleavage of the amyloid precursor protein. |
体外活性 | Anatabine (600 μg/mL; 24 hours; SHSY-5Y cells) treatment shows inhibition of p65 NF-κB phosphorylation. Anatabine (500-1000μg/mL; 30 minutes; SHSY-5Y cells) treatment fully prevents the increase in BACE-1 mRNA levels induced by TNF-α. After 24 hours, Anatabine treatment shows dose-dependent inhibition of BACE-1 protein levels.Anatabine dose-dependently inhibits Aβ1-40 and Aβ1-42 (IC50: 640 μg/mL for both Aβ1-40 and Aβ1-42 in 7W CHO cells). Anatabine inhibits sAPPβ secretion without impacting sAPPα [1]. |
体内活性 | Anatabine (0.5-2 mg/kg; i.p; daily; for 4 days; transgenic mouse) treatment significantly lowers brain soluble Aβ1-40 and Aβ1-42 levels in a transgenic mouse model of Alzheimer's disease [1]. |
分子量 | 544.46 |
分子式 | C22H28N2O14 |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 30 mg/mL (55.10 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容